

# Roger Mclendon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/12187789/roger-mclendon-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17  
papers

10,989  
citations

11  
h-index

17  
g-index

17  
ext. papers

12,419  
ext. citations

17.7  
avg, IF

4.58  
L-index

#	Paper	IF	Citations
17	An integrated genomic analysis of human glioblastoma multiforme. <i>Science</i> , <b>2008</b> , 321, 1807-12	33.3	4419
16	IDH1 and IDH2 mutations in gliomas. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 765-73	59.2	4220
15	Altered telomeres in tumors with ATRX and DAXX mutations. <i>Science</i> , <b>2011</b> , 333, 425	33.3	717
14	The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , <b>2011</b> , 331, 435-9	33.3	576
13	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , <b>2012</b> , 3, 709-22	3.3	439
12	Mutations in CIC and FUBP1 contribute to human oligodendroglioma. <i>Science</i> , <b>2011</b> , 333, 1453-5	33.3	399
11	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <i>Cancer</i> , <b>2005</b> , 104, 1478-86	6.4	73
10	Exomic sequencing of four rare central nervous system tumor types. <i>Oncotarget</i> , <b>2013</b> , 4, 572-83	3.3	57
9	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , <b>2008</b> , 10, 330-40	1	35
8	Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 208-17	6.6	32
7	HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 956-66	1	11
6	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , <b>2015</b> , 133, 730-8	6	10
5	Genetics of glioma1-23		1
4	Pediatric High-Grade Gliomas and DIPG. <i>Molecular Pathology Library</i> , <b>2015</b> , 95-104		
3	Immunotherapy for gliomas91-120		
2	Neuropathology of gliomas146-168		
1	Chemotherapy for gliomas76-90		

